Top

International Journal of Colorectal Disease

Published in:

01-04-2008 | Original Article

Serum sulfatase activity is more elevated in colonic adenomas than cancers

Authors: Malgorzata Matusiewicz, Malgorzata Krzystek-Korpacka, Dorota Diakowska, Krzysztof Grabowski, Katarzyna Augoff, Katarzyna Blachut, Leszek Paradowski, Irena Kustrzeba-Wojcicka, Michal Piast, Teresa Banas

Published in: International Journal of Colorectal Disease | Issue 4/2008

Abstract

Background and aims

Elucidation of molecular basis of the adenomatous polyps (AP) and colorectal cancer (CRC) development is crucial for their prevention, early detection, and treatment. According to the recent discoveries, sulfatases are implied in extracellular matrix remodeling and degradation and also in the regulation of certain signaling pathways. However, their exact role in carcinogenesis remains unclear. Because the majority of CRCs arise from AP, the aim of our studies was the investigation of sulfatase activity in adenomas and adenocarcinomas and verification of possible usefulness of sulfatase activity determination as an indicator of the presence and discrimination between adenomas and carcinomas.

Patient–methods

One hundred twenty individuals were enrolled in the study. We assayed serum sulfatase activity in 79 patients with colorectal neoplasms (38 CRC and 41 AP) and 41 controls. Enzyme activity was determined colorimetrically.

Results

We found statistically higher serum sulfatase activity in patients with colonic neoplasms than in controls (124; 112–139 vs. 79.5; 73–87 U). The activity was more elevated in adenomas (149; 128–173 U) than in cancers (103; 90–112 U). Sulfatase activity exceeded the cutoff value in 71% of AP and 47% of CRC patients. It increased with number of adenomas and tended to decrease with tumor progression.

Conclusions

Sulfatases seem to be involved in the early stages of colonic neoplastic transformation which is reflected in their serum activity. The likelihood of elevated sulfatase activity is almost ten times higher in subjects with than without polyps. Sulfatase upregulation in majority of adenomas and their correlation tendencies warrants reconsideration of sulfatase determination as a possible diagnostic tool.

WGO/OMGE Position Statement. (2004) Colorectal cancer screening and surveillance. World Gastroenterology News 9(Supplement 1–4)

Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C, U.S. Multisociety Task Force on Colorectal Cancer (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology 124:544–560PubMedCrossRef

Diez-Roux G, Ballabio A (2005) Sulfatases and human disease. Annu Rev Genomics Hum Genet 6:355–379PubMedCrossRef

Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A (2005) Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 96:897–905PubMedCrossRef

Doucas H, Garcea G, Neal CP, Manson MM, Berry DP (2005) Changes in the Wnt signaling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer 41:365–379PubMedCrossRef

Katoh M (2005) WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14:1583–1588PubMed

Yi Y-F, Huang Y-R (1998) Arylsulfatase, b-galactosidase and lysozyme in gastric cancer cells and its relationship to invasion. World J Gastroenterol 4:52–54PubMed

Liu D, Shriver Z, Venataraman G, Shabrawi YE, Sasisekharan R (2002) Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. PNAS 99:568–573PubMedCrossRef

Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP (2004) Qsulf1, a heparan sulfate 6-0-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci U S A 101:4833–4838PubMedCrossRef

10.

Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V (2003) Loss of Hsulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278:23107–23117PubMedCrossRef

11.

Green FL, Page DL, Fleming ID, Fritz A, Balch ChM, Haller DG, Morrow M (2002) AJCC Cancer Staging Manual, 6th edn. Springer, New York

12.

Singh J, Tavella D, Di Ferrante N (1975) Measurements of arylsulfatases A and B in human serum. J Pediatr 86:574–576PubMedCrossRef

13.

Li J, Kleeff J, Abiatari I, Kayed H, Giese NA, Felix K, Giese T, Büchler MW, Friess H (2005) Enhanced levels of Hsulf-I interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 4:14. DOI 10.1186/1476-4598-4-14 PubMedCrossRef

14.

Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277:49175–49185PubMedCrossRef

15.

Laidler P, Kowalski D, Silberring J (1991) Arylsulfatase A in serum from patients with cancer of various organ. Clin Chim Acta 204:69–78PubMedCrossRef

16.

Kocak H, Oner–Iyidogan Y, Kocak T, Oner P (2004) Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-α, and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Biochem 37:673–678PubMedCrossRef

17.

Woźniak A, Drewa T, Rozwodowska M, Drewa G, Lambrecht W, Wisniewska I (2002) Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma. Neoplasma 49:10–15PubMed

18.

Turkmen S, Oner P, Cinarv F, Kocak H, Guvenen G, Altun H, Eryavuz Y (2001) Evaluation of leukocyte arylsulfatase-A activity in patients with breast cancer and benign breast disease. Cancer Lett 166:95–101PubMedCrossRef

19.

Morgan LR, Samuels MS, Thomas W, Krementz ET, Meeker W (1975) Arylsulfatase B in colorectal cancer. Cancer 36:2337–2345PubMedCrossRef

20.

Rozwodowska M, Drewa T, Wozniak A, Mila-Kierzenkowska C, Drewa L, Makarewicz R, Maciak R, Musialkiewicz D (2004) Changes in arylsulphatase activity in blood serum in patients with breast cancer before and after treatment. Pol Merkur Lekarski 17:252–254PubMed

21.

Wagenaar-Miller RA, Hanley G, Brandt-Shattuck R, DuBois RN, Bell RL, Matrisian LM, Morgan DW (2003) Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 88:1445–52PubMedCrossRef

Title: Serum sulfatase activity is more elevated in colonic adenomas than cancers
Authors: Malgorzata Matusiewicz
Malgorzata Krzystek-Korpacka
Dorota Diakowska
Krzysztof Grabowski
Katarzyna Augoff
Katarzyna Blachut
Leszek Paradowski
Irena Kustrzeba-Wojcicka
Michal Piast
Teresa Banas
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 4/2008
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-007-0434-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum sulfatase activity is more elevated in colonic adenomas than cancers

Abstract

Background and aims

Patient–methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and aims

Patient–methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2008

Time and rate of sinus formation in pilonidal sinus disease

Treatment of abdominal aortic aneurysm associated with colorectal cancer: presentation of 14 cases and literature review

Philip H. Gordon and Santhat Nivatvongs Principles and practice of surgery for the colon, rectum, and anus

Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers

Occurrence of adenomas in the pouch and small intestine of FAP patients after proctocolectomy with ileoanal pouch construction

Retrieval of colorectal polyps following snare polypectomy: experience of the multiple-suction technique in 602 cases